Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. develops and commercializes biopharmaceutical therapies, with company updates centered on prescription products and clinical or regulatory programs. Recurring news includes financial results, Fanapt sales trends, HETLIOZ commercialization, the U.S. availability of NEREUS (tradipitant) for prevention of vomiting induced by motion, and FDA approval of BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia.
Vanda news also covers development activity for imsidolimab in generalized pustular psoriasis, product-access and commercial-channel updates, investor conference participation, regulatory-policy statements, and corporate governance changes such as board appointments.
Vanda Pharmaceuticals (Nasdaq: VNDA) will participate in three investor conferences in May 2026: Bank of America Global Health Care (May 12, Las Vegas), HCW BioConnect at Nasdaq (May 19, New York) and B. Riley (May 20, Marina Del Rey).
A fireside chat is scheduled for 2:00 p.m. ET on May 19, 2026 at the HCW BioConnect event; the live stream and an archived recording (available ~30 days) can be accessed via Vanda's investor website. Investors should register on conference sites at least 15 minutes early to install any required software.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q1 2026 results and operational milestones on May 6, 2026. Total net product sales were $51.7 million, Fanapt sales rose 26% to $29.6 million, and GAAP net loss was $48.6 million. Cash totaled $202.3 million as of March 31, 2026.
The company launched NEREUS™ via a direct-to-consumer platform, received FDA approval for BYSANTI™, and had its imsidolimab BLA accepted with a PDUFA date of December 12, 2026. Full-year 2026 revenue guidance was raised to $240–$290 million.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced U.S. commercial availability of NEREUS™ (tradipitant) on May 4, 2026 for the prevention of vomiting induced by motion in adults. The FDA approved NEREUS on December 30, 2025 after two Phase 3 trials conducted at sea. NEREUS is available by prescription via retail pharmacies and a direct-to-consumer portal at nereus.us, priced at a cash-pay $85 per dose through the portal versus a $255 list price per dose. Dosing is one or two capsules about an hour before travel.
Vanda (Nasdaq: VNDA) announced U.S. commercial availability of NEREUS™ (tradipitant) on May 1, 2026, for prevention of vomiting induced by motion in adults. The FDA approved NEREUS™ on December 30, 2025. NEREUS™ is an oral NK-1 receptor antagonist and is available by prescription via retail pharmacies and a direct-to-consumer portal at nereus.us.
The company lists a cash-pay price of $85 per dose through the portal versus a $255 standard list price.
Vanda Pharmaceuticals (Nasdaq: VNDA) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after market close. A conference call and simultaneous webcast will be held at 4:30 PM ET the same day to discuss the results and corporate activities.
Investors should register on Vanda's website at least 15 minutes early; a replay will be available from 8:30 PM ET on May 6, 2026 through 11:59 PM ET on May 13, 2026.
Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).
The study findings are included in a Biologics License Application (BLA) for imsidolimab submitted to the U.S. FDA, with a target action date of December 12, 2026.
Vanda Pharmaceuticals (Nasdaq: VNDA) appointed Charles Duncan, Ph.D., to its Board effective April 22, 2026. The board now has seven directors, six independent. Dr. Duncan brings ~30 years of biotechnology equity research experience and founded Sulci Advisors in September 2025. Recent company milestones cited include approvals of NEREUS and BYSANTI, prior Fanapt label expansion, and a pipeline with expected data over the next ~12 months.
Vanda Pharmaceuticals (NASDAQ: VNDA) on April 9, 2026 urged FDA Commissioner Dr. Marty Makary to withdraw a FY 2027 proposal that would remove the 180‑day NDA statutory review requirement and replace it with longer PDUFA/GDUFA performance goals.
The company says the change would extend total review times to 10–12 months, eliminate formal evidentiary hearings, and roll back a recent court-ordered hearing Vanda won after more than 40 years.
Vanda Pharmaceuticals (Nasdaq: VNDA) initiated Thetis, a multicenter, randomized, double-blind Phase 2 trial of NEREUS™ (tradipitant) to prevent vomiting in patients started on high-dose GLP-1 receptor agonists. The company expects topline results by Q4 2026.
Prior Phase 2 data showed vomiting in 29.3% of tradipitant-treated participants versus 58.6% on placebo (p=0.0016), a 50% relative reduction; a key secondary endpoint also favored tradipitant (22.4% vs 48.3%, p=0.0039).
Vanda Pharmaceuticals (Nasdaq: VNDA) criticized the FDA's March 18, 2026 draft guidance on New Approach Methodologies (NAMs), arguing it lacks concrete examples, validation criteria, and citations needed to replace animal tests.
Vanda called for withdrawal and substantial revision, urging clear acceptance pathways, specific validated NAM examples, and collaboration with industry and animal welfare groups.